Alkermes Plc
Change company Symbol lookup
Select an option...
ALKS Alkermes Plc
CPTNW Cepton Equity Warrant Exp 10th Feb 2027 *W EXP 02/10/2027
APPF Appfolio Inc
FMN Federated Hermes Premier Municipal Inc
USCTU TKB Critical Technologies 1
SIEGY Siemens AG
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
Go

Health Care : Biotechnology | Small Cap Growth
Based in Ireland
Company profile

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Closing Price
$27.10
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
978,528

10-day average volume:
1,145,105
978,528

Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference

9:15 am ET December 2, 2022 (PR Newswire) Print

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Conference Details:
Fireside Chat
Date:                 Wednesday, December 7, 2022
Time:                 9:10 - 9:35 a.m. Eastern Standard Time (EST)
Moderator:            Alec Stranahan
Novavax participants: Filip Dubovsky, M.D., Executive Vice President, Chief Medical Officer and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Conference
Event:                Investor Meetings
Date:                 Wednesday, December 7, 2022

RecordingsA replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.comfor 90 days from the date of the conference.

About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.comand connect with us on LinkedIn.

Contacts:InvestorsErika Schultz | 240-268-2022ir@novavax.com

MediaAli Chartan or Giovanna Chandler | 202-709-5563media@novavax.com

https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

https://c212.net/c/img/favicon.png?sn=PH53244&sd=2022-12-02

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2022-virtual-biotech-smid-cap-conference-301692230.html

SOURCE Novavax, Inc.

https://rt.newswire.ca/rt.gif?NewsItemId=PH53244&Transmission_Id=202212020915PR_NEWS_USPR_____PH53244&DateId=20221202

comtex tracking

COMTEX_420070926/1005/2022-12-02T09:15:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.